| 184.71 0.9 (0.49%) | 12-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
BeiGene, Ltd. is a global biotechnology enterprise that operates across the entire pharmaceutical value chain, encompassing the research, development, production, and worldwide commercialization of diverse therapeutic agents. The company's commercially available product lineup includes several important medicines: BRUKINSA, an agent used for relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab, prescribed for R/R classical Hodgkin's lymphoma; REVLIMID, indicated for multiple myeloma; VIDAZA, which addresses myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA, a treatment for giant cell tumor of bone; BLINCYTO, for acute lymphoblastic leukemia; KYPROLIS, another therapy for R/R multiple myeloma; SYLVANT, targeting idiopathic multicentric Castleman disease; QARZIBA, for neuroblastoma; Pamiparib, applicable to various solid tumors; and Pobevcy, indicated for metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). Within its robust clinical development pipeline, BeiGene is actively advancing numerous investigational compounds. Key candidates include Zanubrutinib, a BTK inhibitor designed to combat lymphomas; Tislelizumab, an anti-PD-1 antibody under investigation for a spectrum of solid and hematological cancers; Lifirafenib and BGB-3245, both in trials for melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor targeting NSCLC, melanoma, and other solid tumors. Further expanding its clinical assets are BGB-A333, a PD-L1 inhibitor for diverse solid tumors; Ociperlimab, a TIGIT inhibitor also aimed at various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor for mature B-cell malignancies; BGB-A445, an OX40 agonist antibody for solid tumors; Zanidatamab, a bispecific HER2 inhibitor addressing breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor for a range of solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. BeiGene has also established strategic alliances with prominent industry partners, including Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. The company, incorporated in 2010, maintains its corporate headquarters in Cambridge, Massachusetts.
Sat, 22 Aug 2026
BeiGene, Ltd. - American Depositary Shares (NQ: BGNE - FinancialContent
Thu, 24 Apr 2025
Beigene (BGNE) Stock Price, News & Analysis - Stock Titan
Thu, 25 Jul 2024
BeiGene Ltd (NASDAQ: BGNE) - Share Price - intelligentinvestor.com.au
Thu, 18 Jul 2024
BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer - Business Wire
Wed, 27 Mar 2024
Shareholders in BeiGene (NASDAQ:BGNE) have lost 54%, as stock drops 8.5% this past week - Yahoo Finance
Mon, 26 Feb 2024
BeiGene Ltd (BGNE) Reports Substantial Revenue Growth and Pipeline Progress in Q4 and Full Year 2023 - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|